ArticleFrontiers in oncology2026
A phase II randomized controlled trial of orally administered yeast-derived β-glucan for alleviating chemoradiotherapy-induced oral mucositis in nasopharyngeal carcinoma patients.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with locoregionally advanced nasopharyngeal carcinoma (NPC) undergoing chemoradiotherapy frequently experience severe oral mucositis, with incidence rates ranging from 78.6%-88%. This adverse effect often disrupts therapeutic adherence and negatively impacts nutritional intake. This Phase II trial evaluated oral yeast-derived β-glucan (PGG) for alleviating mucositis and improving nutrition in NPC patients. Methods: Sixty-three stage III-IVa NPC patients receiving radical radiotherapy (70 Gy/33F) with concurrent cisplatin were randomized to PGG supplementation (Experimental group, 5 g/10kg/day, n=30) plus routine care or routine care alone (Control group, n=30). Mucositis severity (RTOG criteria), nutritional parameters (PG-SGA, body composition), and hematological indices were assessed weekly. Results: The experimental Group showed significantly reduced mucositis severity: 70% achieved grade 0-I (vs. 36.7% controls; U = 266.000, p=0.004), with grade III incidence at 6.67% (vs. 26.67%). Nutritional outcomes improved in the experimental Group, evidenced by lower PG-SGA scores at week 4 (10.93 ± 2.60 vs. 12.37 ± 2.39, p=0.03), attenuated weight loss during weeks 3-4 (p<0.05), and increased body fat percentage (p<0.05). No intergroup differences occurred in pain scores, muscle mass, or hematological parameters (leukocytes, hemoglobin, platelets, lymphocyte subsets). Conclusion: Oral PGG significantly reduces severe mucositis incidence and mitigates nutritional deterioration during NPC chemoradiotherapy without added toxicity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.